novo nordisk glp-1 drugs Drops Hims & Hers: Inside the Compounded Crisis Novo Nordisk GLP-1 Drug Meets

FDA Enforcement Actions and Safety Concerns In September 2025, the FDA issued over 50 warning letters to compounders marketing GLP-1 products as generic equivalents to FDA-approved drugs

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP

when tirzepatide is paired with the anti-myostatin agent apitegromab, sarcopenic risk is mitigated by nearly halving lean mass loss compared with dual-incretin monotherapy (14.6% vs

Postprandial reduction in hunger was greater after RYGB than OAGB from baseline to 12 months

Conclusions We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs